Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

Hims & Hers offers rare high growth at value pricing, with DCF models pointing to major upside despite volatility and short ...

WeightWatchers filed for bankruptcy on Tuesday as Americans shunned its offerings in favor of Novo and Lilly drugs and copies ...

Hims & Hers Health (NYSE:HIMS) reported first-quarter earnings on Monday after the market closed and rocketed 18% after ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth. Check out why I ...

Hims & Hers stock price has surged and is nearing its all-time high as investors bet that its strong momentum will continue ...

Hims offers a range of treatment solutions that are customized to meet your specific needs. There's no one-size-fits-all approach to weight loss, after all, and the company's offerings reflect that.

Hims & Hers Health ( HIMS) shares surged 8% Tuesday, a day after the health and wellness platform posted better-than-expected ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...